Do We Get Samples of the Report?

Yes, you will receive a sample copy of the market research report from the sales team when you put a query to us. The sample report is free and offers a brief view of the report and information on data available before you purchase the full-fledged report. Also, we will provide a demo sample for any oncoming study.

How to Buy a Market Report?

Select the report you wish to purchase and proceed to buy it by making an online payment. We use a secured gateway for payment transfers and do not share your financial information with any unconcerned third party.

In Which Format Will I Get the Report?

The report will be delivered in spreadsheet and PDF format. In some cases, PPT formats could be available as well.

In How Much Time I will Get the Report After Purchase?

After confirmation of the payment, you will receive the electronic format of the report at your registered email address in (mention the timeline for the delivery). If you buy a report over a holiday or weekend, we will process the request the next working day.

How Can I Get the Report Customized?

Market studies and reports already contain important data and are ready for distribution to the purchaser. However, if there is any particular query, addition, or customization you require, then contact us on our email id or phone. We will look to accommodate your request and see what can be done at the earliest. The research team will design the report accordingly and discuss the solutions beforehand with you.

How Much Will It Cost to Get a Report Customized?

The price of the customized report will be conveyed to you by our team after we agree on the deliverable. A delivery timeline will be set so that you get the report within the expected date. Any requests for customizations after selling the report will be handled by a separate department and the prices for the same mentioned upfront.

Can I Buy Only a Particular Segment of the Study?

While usually such a request is not accommodated as any market research report is wholesome and the cost of the report is for overall contents, in special cases, we may be able to sell select segments of the report based on your requirements.

Is There Any Available Discount?

Our team will love to support academicians, start-ups, students, and others with consulting and research. Thus, our pricing plan is based on keeping these interests in mind and is already affordable. However, we may have discounts available for particular customer types and reports. So, contact us for more information.

Which Services Are Complimentary Before Purchasing the Report?

We have consumer-centric reports and offer several facilities before selling. You will get a free review and sample report, talk to our customer care team for any additions to be done and meet special requirements, and interact with our analysts for deeper understanding.

Will I Receive a Bill or Invoice for the Report Purchased?

Yes, you will get an invoice for the purchase you made. The invoice will be sent to you electronically on your registered email id.

What If I am Unable to Find the Report in the Catalog?

We have a vast database of market reports and studies and there are a few which may not have been uploaded yet. If you are unable to find the one you want, then get in touch with our sales team by phone or email and we will connect with you for assistance.

How Often Are the Existing Studies Updated?

Not every study is the same. Thus, the update for reports will depend on the ongoing research and changes if any to be incorporated in the document or not.

What If the Report Does Not Contain the Information I Want?

The market research reports are constructed keeping in mind the industry trends, nature of the study, and required inputs. But if you want something more than what is stated in the report, we can help you out with further research if possible. Contact us right away, and we will do the needful to aid you.

Is the Payment Refundable?

Once the payment is done, it is non-refundable because as per the standard policy, the utility of the reports is based on knowledge sharing, and thus, a refund is not possible to make after we have issued you obtain the study. To avoid the hassle, we have a detailed view of the report and its ideas through a sample report.

What If the Payment Fails?

If the payment fails then be assured that you shall receive the money back to the source payment mode from the payment gateway. Aarkstore is not responsible for any loss of payment in the process.

Can I Avail the Report of a Particular Country/Region?

Yes, we can provide a report or segment related to a particular region or geography if we have that feature available for the document.

Do You Offer Support After Purchase?

Yes, we are here to solve any queries you may have for the report from our analyst till a given timeframe. To understand more about this, get in touch with us.

Calcitonin Gene Related Peptide Type 1 Receptor - Drugs In Development, 2021

DESCRIPTION

TABLE OF CONTENTS

RELATED REPORTS

SAMPLE REQUEST

REVIEWS

DESCRIPTION

Calcitonin Gene Related Peptide Type 1 Receptor - Drugs In Development, 2021

Summary

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) pipeline Target constitutes close to 8 molecules. The latest report Calcitonin Gene Related Peptide Type 1 Receptor - Drugs In Development, 2021, outlays comprehensive information on the Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Calcitonin receptor-like (CALCRL) also known as the calcitonin receptor-like receptor (CRLR) is a G protein-coupled receptor. The association of CALCRL with different RAMP proteins produces different receptors which with RAMP1 acts as a receptor for calcitonin-gene-related peptide, with RAMP2 acts as a receptor for adrenomedullin-1and with RAMP3 act as a receptor for adrenomedullin-2. It plays an important role in treatment of migraine. The molecules developed by companies in Pre-Registration, Phase III, Preclinical and Discovery stages are 3, 1, 3 and 1 respectively. Report covers products from therapy areas Central Nervous System, Undisclosed, Cardiovascular, Dermatology, Immunology, Infectious Disease and Oncology which include indications Migraine, Unspecified, Trigeminal Neuralgia (Tic Douloureux), Coronavirus Disease 2019 (COVID-19), Pain, Pancreatic Cancer, Psoriasis, Resistant Hypertension, Rosacea and Traumatic Brain Injury.

Furthermore, this report also reviews key players involved in Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL)
- The report reviews Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics and enlists all their major and minor projects
- The report assesses Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

TABLE OF CONTENTS

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Overview
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Companies Involved in Therapeutics Development
AbbVie Inc
Adepthera LLC
Amgen Inc
Biohaven Pharmaceutical Holding Company Ltd
Modulus Oncology Ltd
Shanghai Junshi Bioscience Co Ltd
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Drug Profiles
atogepant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
erenumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HTL-0022562 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JS-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rimegepant sulfate ODT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHF-1036 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target CALCRL and RAMP for Resistant Hypertension - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zavegepant hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Dormant Products
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Discontinued Products
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Product Development Milestones
Featured News & Press Releases
Jun 23, 2021: Sosei Heptares initiates phase 1 trial with novel small-molecule CGRP antagonist under collaboration with Biohaven
Jun 23, 2021: Amgen announces approval Of Aimovig (frenumab) in Japan for the suppression of onset of migraine attacks in adults
Jun 03, 2021: Biohaven announces presentations on Zavegepant at the 2021 virtual annual scientific meeting of the American Headache Society
Jun 03, 2021: Biohaven showcases CGRP-antagonist franchise data including Nurtec ODT (rimegepant), now approved to treat and prevent migraine attacks, and presentations at the 2021 virtual annual scientific meeting of the American Headache Society
May 27, 2021: FDA approves Biohavens Nurtec ODT (Rimegepant) for prevention: now the first and only migraine medication for both acute and preventive treatment
May 14, 2021: Biohavens Nurtec ODT signs as primary partner with Rick Ware Racing for 2021 NTT INDYCAR Series Program
Apr 13, 2021: Biohaven announces presentations on Zavegepant at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting
Apr 13, 2021: Biohaven announces presentations on rimegepant at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting
Apr 07, 2021: AbbVie to present data on Atogepant at the 2021 American Academy of Neurology (AAN) Annual Meeting
Mar 30, 2021: U.S. FDA accepts AbbVies New Drug Application for Atogepant for the preventive treatment of Migraine
Mar 30, 2021: Biohaven initiates enrolment in migraine treatment trial
Mar 11, 2021: Biohavens nurtec ODT approved in United Arab Emirates for acute treatment of migraine
Mar 10, 2021: Biohavens Nurtec ODT approved in Israel for acute treatment of migraine
Jan 25, 2021: Biohaven announces preliminary 4Q2020 net product revenue for NURTEC ODT
Jan 18, 2021: Biohaven signs Cody Ware as driver for Nurtec ODT Chevrolet for the 2021 NASCAR Cup series season
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by AbbVie Inc, 2021
Pipeline by Adepthera LLC, 2021
Pipeline by Amgen Inc, 2021
Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2021
Pipeline by Modulus Oncology Ltd, 2021
Pipeline by Shanghai Junshi Bioscience Co Ltd, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021

List Of Figures

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

RELATED REPORTS

Receptor Activity Modifying Protein 3 (Calcitonin Receptor Like Receptor Activity Modifying Protein 3 or RAMP3) - Drugs in Development, 2021

Receptor Activity Modifying Protein 3 (Calcitonin Receptor Like Receptor Activity Modifying Protein 3 or RAMP3) - Drugs in Development, 2021Receptor Activity Modifying Protein 3 (Calcitonin Receptor Like Receptor Activity Modifying

USD 3000 View Report

Receptor Activity Modifying Protein 2 (Calcitonin Receptor Like Receptor Activity Modifying Protein 2 or CRLR Activity Modifying Protein 2 or RAMP2) - Drugs in Development, 2021

Receptor Activity Modifying Protein 2 (Calcitonin Receptor Like Receptor Activity Modifying Protein 2 or CRLR Activity Modifying Protein 2 or RAMP2) - Drugs in Development, 2021Receptor Activity Modifying Protein 2

USD 3000 View Report

Calcitonin Gene Related Peptide - Pipeline Review, H2 2020

Calcitonin Gene Related Peptide - Pipeline Review, H2 2020According to the recently published report Calcitonin Gene Related Peptide - Pipeline Review, H2 2020; Calcitonin Gene Related Peptide (CGRP) pipeline Target

USD 3500 View Report

Calcitonin Gene Related Peptide - Pipeline Review, H1 2020

Calcitonin Gene Related Peptide - Pipeline Review, H1 2020Calcitonin Gene Related Peptide (CGRP) pipeline Target constitutes close to 10 molecules. The latest report Calcitonin Gene Related Peptide - Pipeline Review,

USD 3500 View Report

SAMPLE REQUEST

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

REVIEWS

There is no Reviews available

Search and Get the Latest Market Research Reports

Calcitonin Gene Related Peptide Type 1 Receptor - Drugs In Development, 2021

Receptor Activity Modifying Protein 3 (Calcitonin Receptor Like Receptor Activity Modifying Protein 3 or RAMP3) - Drugs in Development, 2021

Receptor Activity Modifying Protein 2 (Calcitonin Receptor Like Receptor Activity Modifying Protein 2 or CRLR Activity Modifying Protein 2 or RAMP2) - Drugs in Development, 2021

Calcitonin Gene Related Peptide - Pipeline Review, H2 2020

Calcitonin Gene Related Peptide - Pipeline Review, H1 2020

FAQs